Compounds > uracil

uracil and linagliptin

uracil has been researched along with linagliptin in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's21 (84.00)24.3611
2020's4 (16.00)2.80

Authors

AuthorsStudies
Scheen, AJ2
Gerich, J1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A1
Gallwitz, B1
Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM1
Ishikawa, M; Yamada, Y1
Bakris, GL; Flynn, C1
Charbonnel, B; Dejager, S; Schweizer, A1
Hu, W; Lu, X; Tu, Z; Wang, S; Xie, H; Xu, H; Yang, L; Zeng, L; Zeng, S; Zhang, G; Zhang, X; Zhao, X1
Tibaldi, JM1
Athyros, VG; Elisaf, MS; Filippatos, TD1
Ding, YY; Hu, WH; Song, HR; Wang, SC; Xie, H; Zeng, LL; Zeng, SG1
Kong, L; Lai, ZW; Li, C; Liu, J; Sun, H; Wen, X1
Bonora, E; Cigolini, M1
Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A1
Arulmozhiraja, S; Ishitsubo, E; Matsuo, N; Okazaki, S; Shimano, H; Tokiwa, H1
Lingvay, I1
Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A1
Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB1
Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM1
Akimoto, H; Asai, S; Nakayama, T; Nishida, Y; Takahashi, Y; Tezuka, K1
Hardman, TC; Hucke, O; Klein, T; Nar, H; Schnapp, G1
Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B1

Reviews

12 review(s) available for uracil and linagliptin

ArticleYear
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Clinical pharmacokinetics, 2010, Volume: 49, Issue:9

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin

2010
DPP-4 inhibitors: what may be the clinical differentiators?
    Diabetes research and clinical practice, 2010, Volume: 90, Issue:2

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin

2010
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Hospital practice (1995), 2011, Volume: 39, Issue:1

    Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin

2011
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6

    Topics: Administration, Oral; Animals; Boronic Acids; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Linagliptin; Piperidines; Purines; Quinazolines; Uracil

2011
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Diabetes & metabolism, 2012, Volume: 38, Issue:2

    Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain

2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
    Current diabetes reviews, 2012, Volume: 8, Issue:3

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin

2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
    Nature reviews. Nephrology, 2013, Volume: 9, Issue:3

    Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin

2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Hospital practice (1995), 2013, Volume: 41, Issue:2

    Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin

2013
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
    Advances in therapy, 2014, Volume: 31, Issue:3

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss

2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin

2014
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:4

    Topics: Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endpoint Determination; Humans; Hypoglycemic Agents; Linagliptin; Meta-Analysis as Topic; Observational Studies as Topic; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil

2016
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7

    Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil

2017

Other Studies

13 other study(ies) available for uracil and linagliptin

ArticleYear
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia

2011
[Therapeutic use and adverse events of incretin-related drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin

2012
Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
    European journal of medicinal chemistry, 2013, Volume: 68

    Topics: Animals; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Activation; Inhibitory Concentration 50; Linagliptin; Male; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Piperidines; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Uracil

2013
[A novel dipeptidyl peptidase IV inhibitors developed through scaffold hopping and drug splicing strategy].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2014, Volume: 49, Issue:1

    Topics: Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Drug Discovery; Humans; Hypoglycemic Agents; Linagliptin; Molecular Structure; Piperidines; Structure-Activity Relationship; Uracil

2014
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
    European journal of medicinal chemistry, 2014, Aug-18, Volume: 83

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Linagliptin; Models, Molecular; Piperidines; Protein Conformation; Purines; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Uracil

2014
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Clinical therapeutics, 2016, Volume: 38, Issue:8

    Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin

2016
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Linagliptin; Molecular Docking Simulation; Piperidines; Pyrazoles; Sitagliptin Phosphate; Thiazolidines; Uracil

2016
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
    Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:3

    Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin

2018
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:6

    Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil

2018
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
    The Journal of dermatology, 2020, Volume: 47, Issue:3

    Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult

2020
Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
    BMC pharmacology & toxicology, 2020, 04-21, Volume: 21, Issue:1

    Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Linagliptin; Lipid Metabolism; Lipoproteins, HDL; Male; Middle Aged; Piperidines; Pyrazoles; Sitagliptin Phosphate; Thiazolidines; Triglycerides; Uracil; Vildagliptin

2020
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
    ChemMedChem, 2021, 05-06, Volume: 16, Issue:9

    Topics: Adamantane; Antiviral Agents; Coronavirus 3C Proteases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Enzyme Assays; Heterocyclic Compounds; Linagliptin; Piperidines; SARS-CoV-2; Sitagliptin Phosphate; Uracil

2021
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin

2021
chemdatabank.com